Abstract | PURPOSE: METHODS: Eight patients with XLRS and foveal cystic-appearing spaces by fundus examination and by optical coherence tomography (OCT) were treated with a topical form of carbonic anhydrase inhibitor. Changes in "foveal thickness" and "foveal zone thickness" were measured by OCT, and changes of best-corrected visual acuity were measured by Early Treatment Diabetic Retinopathy Study (ETDRS) charts. RESULTS: Seven of eight patients treated with 2% dorzolamide had a noticeable reduction in foveal thickness as well as cystic-appearing spaces by OCT. This reduction was found in both eyes in four of these patients and in one eye in one patient after 1 month of treatment. After an additional 1 month to 2 months of the same treatment regimen, two additional patients also had a noticeable reduction in foveal thickness as well as cystic-appearing spaces. Of these seven patients who had an improvement shown by OCT with treatment, five also had improvement of their visual acuity by >or=7 letters in at least one eye on ETDRS charts. CONCLUSION: The present study shows the efficacy of topical dorzolamide for treating foveal cystic-appearing lesions in patients with XLRS.
|
Authors | Marsha A Apushkin, Gerald A Fishman |
Journal | Retina (Philadelphia, Pa.)
(Retina)
Vol. 26
Issue 7
Pg. 741-5
(Sep 2006)
ISSN: 0275-004X [Print] United States |
PMID | 16963845
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Carbonic Anhydrase Inhibitors
- Ophthalmic Solutions
- Sulfonamides
- Thiophenes
- dorzolamide
|
Topics |
- Administration, Topical
- Adult
- Carbonic Anhydrase Inhibitors
(therapeutic use)
- Cysts
(diagnosis, drug therapy)
- Fovea Centralis
(drug effects)
- Humans
- Middle Aged
- Ophthalmic Solutions
(therapeutic use)
- Prospective Studies
- Retinoschisis
(diagnosis, drug therapy)
- Sulfonamides
(therapeutic use)
- Thiophenes
(therapeutic use)
- Tomography, Optical Coherence
- Visual Acuity
|